HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY)
The HARLEY study is exploring a specific heart problem called transthyretin cardiac amyloidosis. This condition happens when abnormal proteins build up in the heart, making it stiff and less able to pump blood properly. Researchers want to understand if how fast or slow a person's heart beats (their heart rate) has an impact on their overall quality of life. This means looking at things like how they feel day-to-day, their energy levels, and their ability to do normal activities. The study involves looking at information from people who already have this condition and are receiving treatment, to better understand how heart rate might play a role in their well-being.
At a glance
What is this study about?
The HARLEY study is focused on a heart condition known as transthyretin cardiac amyloidosis. In simple terms, this is when special proteins, called transthyretin, don't fold correctly and start to build up as deposits in the heart muscle. Over time, these deposits make the heart stiff and less efficient at pumping blood around the body, which can lead to various symptoms and impact a person's life.
Researchers in the HARLEY study are particularly interested in how a person's heart rate might affect their quality of life if they have this condition. Your heart rate is simply how many times your heart beats in a minute. We know that heart rate can be important in many heart conditions, and this study aims to see if it makes a difference to how people with transthyretin cardiac amyloidosis feel and cope with their daily activities.
This study is considered a "Phase IV" study, which means it's looking at treatments that are already in use. It's about gathering more information on how these treatments, and other factors like heart rate, affect people in the real world. By understanding the link between heart rate and quality of life, doctors might be able to offer better advice or adjust treatments to help people with this condition live more comfortably and improve their well-being.
Key takeaways
- The HARLEY study investigates how heart rate affects quality of life in people with transthyretin cardiac amyloidosis.
- It aims to better understand the condition and help improve patient well-being.
- This is a Phase IV study, meaning it looks at existing treatments and patient experiences.
- Participation mainly involves sharing existing health information, not new experimental treatments.
- It's open to adults aged 18 or older, both men and women, with the specific heart condition.
Who may be eligible?
To be considered for this study, you would generally need to be an adult, aged 18 years or older. There isn't an upper age limit mentioned, so older adults could also be included. Both men and women are welcome to take part in this research.
The main requirement is that you have been diagnosed with transthyretin cardiac amyloidosis. This study is about understanding the condition better in various people who have it. It's not about testing a brand new treatment, but rather observing and gathering information from people already living with the condition and likely receiving care for it.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with transthyretin cardiac amyloidosis?
- Are you comfortable sharing your routine medical information?
- Are you happy to complete questionnaires about your health and feelings?
What does participation involve?
As a Phase IV study, taking part in HARLEY will likely involve reviewing existing medical information rather than undergoing new experimental treatments. You might be asked to share your past and present medical details, including information about your heart rate measurements and how you feel about your overall health and quality of life. There might be some questionnaires or interviews to complete. You would not typically receive any new medication directly from this study, but your current treatments would continue as prescribed by your own doctor. There wouldn't be additional visits specifically for the study beyond your usual medical appointments. The total time you'd be involved might vary depending on how much information is collected, but it's generally about using data gathered during routine care.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is 'transthyretin cardiac amyloidosis'?
It's a heart condition where special proteins build up in the heart, making it stiff and harder to pump blood properly.
What does a 'Phase IV' study mean?
It means the study is looking at treatments that are already approved and in use, to gather more information about how they work in real-world patients.
Will I get new medicine if I join this study?
No, this study is about observing and collecting information on existing treatments and your health, not testing new medicines.
Who can take part in the HARLEY study?
Adults aged 18 or older with transthyretin cardiac amyloidosis, both men and women, are generally eligible.
What is 'quality of life' in this study?
It refers to how well you feel day-to-day, your energy, and your ability to do normal activities, and how these are affected by your health.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.